Business
Apollo Technology Capital Corporation Poses Questions That MediPharm Shareholders Should Ask on Management's Conference Call with Shareholders
Apollo Technology Capital Corporation Poses Questions That MediPharm Shareholders Should Ask on M...
About this update from Medipharm Labs Corp.
[{"type":"text","content":"\n\n\n\n Apollo Technology Capital Corporation Poses Questions That MediPharm Shareholders Should Ask on Management's Conference Call with Shareholders\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n Company Has Suspended Calls Since the Second Quarter of 2024 to Avoid Facing the Music for Board's and Management Team's Destruction of 99% of Stock's Value, Costing Shareholders\n \n $1\n \n Billion\n \n\n\n\n Conference Call is a Blatant, Self-Serving Reaction by a Management Team Running Scared Following Apollo Capital's Intention to Nominate Six Highly Qualified Directors to MediPharm's Board\n \n\n\n\n\n Shareholders Deserve Answers From Management About Massive Underperformance, Failed\n \n Operational Strategies, Poor Capital Allocation, Outrageous Compensation, and Lack of Transparency\n \n\n\n\n Apollo Capital's Nominees Bring Significant Turnaround, M&A, and Operational Experience in Cannabis and Adjacent Industries, and Will Execute Plan to Restore Value for ALL MediPharm Shareholders\n \n\n\n\n Urges MediPharm Shareholders to Vote for Wholesale Change at Annual Meeting\n \n\n\n\n\n TORONTO\n \n\n ,\n \n\n May 14, 2025\n \n\n /CNW/ -- Apollo Technology Capital Corporation (\"Apollo Capital\"), which together with its affiliates and associates collectively is one of the largest shareholders of MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (\"MediPharm\", \"MediPharm Labs\", or the \"Company\"), owning approximately 3.0% of the Company's common stock, today posed several critical questions that shareholders should ask MediPharm management on this morning's conference call following its first quarter 2025 earnings report. CEO\n \n David Pidduck\n \n and his management team have not held a call with shareholders since the second quarter of 2024 to avoid having to defend themselves after destroying 99% of the value of the company's stock, or nearly\n \n $1 billion\n \n .\n \n\n The conference call is clearly a frightened reaction to Apollo Capital's recent...